Phenylpropanolamine (HCl)

Phenylpropanolamine (HCl) is indirectly acting sympathomimetic with prominent peripheral adrenergic effects and weak central stimulant action. Phenylpropanolamine (HCl) is mainly used as a nasal decongestant. Phenylpropanolamine (HCl) is also used as anorexiant in obesity and to treat urinary incontinence.

Phenylpropanolamine (HCl) is primarily indicated in conditions like Appetite suppresser, Cold, Congestion, Cough, Urinary incontinence.

Phenylpropanolamine (HCl) is contraindicated in conditions like Glaucoma, Hypertension, Hyperthyroidism, Prostatic hypertrophy, Intestinal obstruction.

Phenylpropanolamine (HCl) produces potentially life-threatening effects which include Hypertension. which are responsible for the discontinuation of Phenylpropanolamine (HCl) therapy. The signs and symptoms that are produced after the acute overdosage of Phenylpropanolamine (HCl) include Epileptic seizures, Hallucinations, Psychosis. The symptomatic adverse reactions produced by Phenylpropanolamine (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Palpitation, Tremors, Chest tightness.

Use topical decongestant (phenylpropanolamine) only in acute conditions, not longer than 3 to 5 days. It should be used sparingly in all patients, especially in infants, children and in cardiac patients. Avoid continuous use for longer than 3 months.

Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

25 to 50 mg (38 (37.5)) 4 hourly PO —

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

Phenylpropanolamine (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAcebutololAtropine (Sulphate)Bromocriptine (Mesylate)Risk of toxicity when Bromocriptine given wih Phenylpropanolamine.MajorDebrisoquine (Sulphate)Doxepin (HCl)EphedrineThere is an increase in blood pressure and heart rate if this combination is used.ModerateThis combination is used cautiously and should monitor pulse and blood pressure.FurazolidoneCoadministration results hypertension and hyperpyrexia by sympathomimetic effect due to increase norepinephrine storage in neurons and increased release of catecholamine.MajorCoadministration should not be given if necessary then 14 days gap should be given during the initiation of other therapy.GuanethidineIndomethacinCoadministration of these agents causes increased sensitivity to sympathomimetic-induced blood pressure by inhibiting prostaglandin synthesis results in severe hypertension.ModerateClosely monitor for blood pressure of patient.LinezolidLisurideMoclobemideSibutramineThioridazine (HCl)Thioridazine antagonize the pharmacological effects of phenylpropanolamine. Conversely, phenylpropanolamine decreases the neuroleptic efficacy of thioridazine.ModerateCoadministration is considered contraindicated. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Tab, Cap Store at room temperature. Protect from Sunlight.